大行評級丨中銀國際:上調三生製藥目標價至21.8港元 維持“買入”評級
中銀國際發表研究報告指,三生製藥日前公佈與輝瑞就PD-1/VEGF雙特異性抗體(SSGJ-707)達成中國以外的全球許可轉讓合作,交易包括12.5億美元的許可首付款付款、最多48億美元的里程碑付款,以及雙位數百分比的分級銷售里程碑付款。該行認爲交易規模超出市場預期,將交易前期款項納入集團2025財年的收入預測,並將SSGJ-707在2029財年之後的海外貢獻納入評估範圍,目標價由12.7港元上調至21.8港元,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.